# Proscia

> Digital-pathology workflow and AI software for laboratories and biopharma.

## Why it is interesting

Agilent's agreement to acquire Proscia would combine diagnostic instruments and staining reagents with an open software layer, making pathology data a foundation for AI-enabled diagnostics and drug development.

## Profile

- **Latest funding:** Growth financing — $50M (March 2025)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $50M
- **Stage:** growth
- **Status:** private
- **Industries:** ai-ml, healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-10-14
- **Latest funding investors:** Undisclosed investors

## Key facts

- Agilent agreed to pay $240M at closing plus up to $30M in performance payments.
- Proscia reported more than $18M of trailing-twelve-month revenue.

## Funding history

- Growth financing · $50M · March 2025
  Source: https://proscia.com/press-release/proscia-raises-50m-to-advance-ai-driven-pathology-and-deliver-the-future-of-precision-medicine

## Related articles

- https://venturecapitaltracker.com/agilent-proscia-240m-digital-pathology-acquisition

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 14, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/proscia